Mammogen Appoints DeeDee DeMan to Chair Board of Directors, Aims for Growth in Women’s Health

Mammogen Appoints DeeDee DeMan as Chairwoman of the Board

Mammogen, a pioneering company focused on predictive health for women, recently appointed Denise "DeeDee" DeMan as the Chairwoman of its Board of Directors. This announcement marks a crucial step in the company's journey to redefine early disease detection, particularly in the realm of women's health.

DeeDee DeMan, a highly respected figure within global life sciences, brings over five decades of experience in building effective leadership teams for some of the healthcare industry's most notable companies. As the founder and CEO of Bench International, she has a proven track record of placing C-level executives and board members in organizations dedicated to healthcare innovation. Her deep expertise is expected to enhance Mammogen's commitment to inclusive governance, a principle demonstrated through initiatives such as Bench's renowned Bank of Women®.

Mammogen's transition from a research-focused organization to a clinical-stage entity ready for commercialization highlights its increasing significance in the healthcare industry. The company is on the verge of launching its flagship product, a blood-based early detection test for breast cancer named genTRU™. This groundbreaking assay strives to identify breast cancer at its most treatable stages, thereby preserving the quality of life for women. Studies supporting the genTRU™ assay show an impressive sensitivity rate of over 99% and a specificity of 89% for Stage I disease, indicating robust clinical validation.

DeDee DeMan expressed her enthusiasm regarding this appointment, stating, "Mammogen embodies the validation of science and purpose-driven leadership—essential traits of companies poised to revolutionize clinical landscapes. I am honored to lead as Chairwoman and look forward to guiding Mammogen through its next growth phase, ensuring our governance aligns with its innovative scientific endeavors."

Mammogen's commitment to addressing an urgent need in healthcare is underscored by the fact that over 25 million U.S. women are currently at risk for breast cancer, as indicated by the Mammography Quality Standards Act (MQSA) Guidelines. Under DeMan's leadership, the Board aims to enhance Mammogen's position in the healthcare market and accelerate its development, given global demand for effective screening solutions.

Elizabeth Cormier-May, CEO of Mammogen, reinforced the importance of DeMan's role at this pivotal moment in the company's strategy. "DeeDee’s choice to join Mammogen now reflects our ambition to scale and maintain the integrity of scientific innovation. Her unparalleled expertise in governance and leadership is critical as we navigate towards a future where we can deliver transformative healthcare solutions."

As Chairwoman, DeMan is set to outline the governance strategy of Mammogen’s board while assisting the company in fortifying its footing in the industry as it advances towards commercialization. This collaboration represents more than a leadership move; it's a commitment to change in the healthcare sector that prioritizes women's health.

To learn more about Mammogen and its innovative offerings, visit Mammogen's website. Also, discover more about Bench International and their extensive contributions to the life sciences sector at Bench International's website.

Mammogen's mission centers on revolutionizing women's health diagnostics, seeking to provide accessible and high-quality early detection methods through cutting-edge scientific advancements. It's a future committed to not just detection but also to uplifting the lives of countless women through innovation.